Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President
Nichi-Iko Pharmaceutical is now in the final phase of deliberations with Kyowa Pharmaceutical Industry on their potential collaboration in generic manufacturing, the company’s president Shingo Iwamoto revealed to Jiho in an interview on January 28. The two generic makers aim…
To read the full story
Related Article
- Generic Industry Shakeup Advances as Teva Takeda Joins JWP-Medipal Group
December 9, 2024
- Nichi-Iko to Join Forces with Kyowa in Generic Production, Eyeing Reorganization
July 24, 2024
- Kyowa Pharma Reveals Fudged Accelerated Stability Test of Mestinon
April 17, 2024
- Kyowa Pharma Joins Medipal-JWP JV, Now Sister Firm to Nichi-Iko
March 6, 2024
- Kyowa Pharma Hit by Biz Suspension over Manufacturing Flaws, Record Fabrications
March 29, 2022
- Unison Capital Shows Rising Presence with Kyowa Deal, PE Fund Potential Catalyst for Industry Shakeup?
November 22, 2019
BUSINESS
- Susaki City to Subsidize Beyfortus Use in Healthy Babies
April 3, 2025
- Ultomiris, Soliris Bolster Labels for gMG in Japan: Alexion
April 3, 2025
- Shionogi Grants Cefiderocol Rights to Clinigen Unit in Australia/New Zealand
April 3, 2025
- Cheplapharm Completes Tarceva Transfer, Announces Hydrea Acquisition in Japan
April 3, 2025
- Boehringer Will Wait and See Impact of Trump Tariffs, FDA Layoffs: CEO
April 3, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…